Zomedica Pharmaceuticals Corp. to Present at Jefferies 2018 London Healthcare Conference and LD Micro Main Event XI

- NYSE Companies
  0

ANN ARBOR, Mich., Nov. 12, 2018 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it will present at the Jefferies 2018 London Healthcare Conference on November 15 in London, UK, and at the LD Micro Main Event XI on December 4 in Los Angeles, CA.

Chief Financial Officer Shameze Rampertab, CPA, CA, will provide an overview of Zomedica’s business during his live presentations at both conferences and will be available to participate in one-on-one meetings with investors registered to attend the conferences.

Jefferies 2018 London Healthcare Conference
Date: Thursday, November 15, 2018
Time: 5:20 p.m. GMT (12:20 p.m. ET)
Location: London, UK

LD Micro Main Event XI
Date: Tuesday, December 4, 2018
Time: 4:30 p.m. PT (7:30 p.m. ET)
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA

Investors and other interested parties will be able to access a live webcast of both presentations by visiting Zomedica’s website at http://investors.zomedica.com. A replay of the audio webcasts and copies of each presentation will be accessible on the Zomedica website following the events.

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Investor Relations Contact
Shameze Rampertab, CPA, CA
[email protected]
+1 647.283.3630

PCG Advisory Group
Kirin Smith, COO
[email protected]
+1 646.863.6519
www.pcgadvisory.com

Media Contact
Andrea Eberle
[email protected]
+1 734.369.2555